Structure

InChI Key POGQSBRIGCQNEG-UHFFFAOYSA-N
Smile NC(=O)c1cn(Cc2c(F)cccc2F)nn1
InChI
InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

Physicochemical Descriptors

Property Name Value
Molecular Formula C10H8F2N4O
Molecular Weight 238.2
AlogP 0.7
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 3.0
Polar Surface Area 73.8
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 17.0

Pharmacology

Action Mechanism of Action Reference
BLOCKER Sodium channel alpha subunit blocker DailyMed Wikipedia
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Lyase
- - - 344 -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Lennox Gastaut Syndrome 4 D065768 ClinicalTrials
Pain 2 D010146 ClinicalTrials

Side Effects from Label

Side effects Relative Frequency (%) Labels
Nervous system disorders Headache 27.0
Nervous system disorders Headache
Cardiac disorders Dizziness 19.0
Nervous system disorders Somnolence 17.0
Gastrointestinal disorders Vomiting 17.0
General disorders and administration site conditions Asthenia 16.0
General disorders and administration site conditions Fatigue 16.0
Nervous system disorders Headache 16.0
Cardiac disorders Dizziness
Gastrointestinal disorders Nausea 12.0
Nervous system disorders Somnolence 11.0
General disorders and administration site conditions Asthenia
General disorders and administration site conditions Fatigue
General disorders and administration site conditions Asthenia 9.0
Eye disorders Diplopia 9.0
General disorders and administration site conditions Fatigue 9.0
Gastrointestinal disorders Nausea
Nervous system disorders Somnolence
General disorders and administration site conditions Asthenia
Cardiac disorders Dizziness 8.0
General disorders and administration site conditions Fatigue
Nervous system disorders Headache
Gastrointestinal disorders Nausea 7.0
Gastrointestinal disorders Vomiting
Cardiac disorders Dizziness
Eye disorders Nystagmus 6.0
Nervous system disorders Tremor 6.0
Eye disorders Vision blurred 6.0
General disorders and administration site conditions Decreased appetite 5.0
Infections and infestations Influenza 5.0
Infections and infestations Nasopharyngitis 5.0
Eye disorders Nystagmus
Nervous system disorders Tremor
Gastrointestinal disorders Vomiting 5.0
Nervous system disorders Ataxia 4.0
Skin and subcutaneous tissue disorders Dermatitis 4.0
Eye disorders Diplopia 4.0
Infections and infestations Influenza
Skin and subcutaneous tissue disorders Rash 4.0
Gastrointestinal disorders Vomiting
Gastrointestinal disorders Abdominal pain upper 3.0
Psychiatric disorders Aggression 3.0
Nervous system disorders Agitation 3.0
Psychiatric disorders Anxiety 3.0
Musculoskeletal and connective tissue disorders Back pain 3.0
Infections and infestations Bronchitis 3.0
Gastrointestinal disorders Constipation 3.0
Eye disorders Diplopia
Nervous system disorders Disturbance in attention 3.0
Cardiac disorders Dizziness 3.0
Gastrointestinal disorders Dyspepsia 3.0
Infections and infestations Ear infection 3.0
General disorders and administration site conditions Gait disturbance 3.0
Infections and infestations Nasopharyngitis
Gastrointestinal disorders Nausea
Skin and subcutaneous tissue disorders Pruritus 3.0
Infections and infestations Sinusitis 3.0
Ear and labyrinth disorders Vertigo 3.0
Gastrointestinal disorders Abdominal pain upper
Psychiatric disorders Aggression
Psychiatric disorders Anxiety
General disorders and administration site conditions Asthenia 2.0
Infections and infestations Bronchitis
Gastrointestinal disorders Constipation
Convulsion 2.0
General disorders and administration site conditions Decreased appetite
Skin and subcutaneous tissue disorders Dermatitis
Skin and subcutaneous tissue disorders Dermatitis 2.0
Gastrointestinal disorders Dyspepsia
General disorders and administration site conditions Fatigue 2.0
Nervous system disorders Headache 2.0
Skin and subcutaneous tissue disorders Rash
Skin and subcutaneous tissue disorders Rash 2.0
Infections and infestations Sinusitis
Eye disorders Vision blurred
Nervous system disorders Agitation
General disorders and administration site conditions Asthenia
Nervous system disorders Ataxia
Nervous system disorders Ataxia 1.0
Musculoskeletal and connective tissue disorders Back pain
Convulsion
Skin and subcutaneous tissue disorders Dermatitis
Eye disorders Diplopia
Nervous system disorders Disturbance in attention
Cardiac disorders Dizziness
Infections and infestations Ear infection
General disorders and administration site conditions Fatigue
General disorders and administration site conditions Gait disturbance
Nervous system disorders Headache
Gastrointestinal disorders Nausea 1.0
Skin and subcutaneous tissue disorders Rash
Ear and labyrinth disorders Vertigo
Gastrointestinal disorders Vomiting 1.0

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Nervous system disorders
23.94
General disorders and administration site conditions
16.09
Metabolism and nutrition disorders
12.1
Investigations
7.97
Gastrointestinal disorders
7.93
Psychiatric disorders
7.26
Injury, poisoning and procedural complications
3.68
Hepatobiliary disorders
3.65
Respiratory, thoracic and mediastinal disorders
3.25
Infections and infestations
3.11
Musculoskeletal and connective tissue disorders
2.35
Skin and subcutaneous tissue disorders
2.35

Cross References

Resources Reference
CAS NUMBER 106308-44-5
ChEBI 134966
ChEMBL CHEMBL1201754
DrugBank DB06201
DrugCentral 3534
EPA CompTox DTXSID1046506
FDA SRS WFW942PR79
Guide to Pharmacology 7470
PharmGKB PA166131606
PubChem 129228
SureChEMBL SCHEMBL230448
ZINC ZINC000000007782